Dipartimento della Donna, del Bambino e di Chirurgia Generale e Specialistica, Second University of Naples, Via Luigi De Crecchio, 4, Naples 80138, Italy.
BMC Med Genet. 2014 Apr 26;15:44. doi: 10.1186/1471-2350-15-44.
Diagnosis within RASopathies still represents a challenge. Nevertheless, many efforts have been made by clinicians to identify specific clinical features which might help in differentiating one disorder from another. Here, we describe a child initially diagnosed with Neurofibromatosis-Noonan syndrome. The follow-up of the proband, the clinical evaluation of his father together with a gene-by-gene testing approach led us to the proper diagnosis.
We report a 8-year-old male with multiple café-au-lait macules, several lentigines and dysmorphic features that suggest Noonan syndrome initially diagnosed with Neurofibromatosis-Noonan syndrome. However, after a few years of clinical and ophthalmological follow-up, the absence of typical features of Neurofibromatosis type 1 and the lack of NF1 mutation led us to reconsider the original diagnosis. A new examination of the patient and his similarly affected father, who was initially referred as healthy, led us to suspect LEOPARD syndrome, The diagnosis was then confirmed by the occurrence in both patients of a heterozygous mutation c.1403 C > T, p.(Thr468Met), of PTPN11. Subsequently, the proband was also found to have type-1 Arnold-Chiari malformation in association with syringomyelia.
Our experience suggests that differential clinical diagnosis among RASopathies remains ambiguous and raises doubts on the current diagnostic clinical criteria. In some cases, genetic tests represent the only conclusive proof for a correct diagnosis and, consequently, for establishing individual prognosis and providing adequate follow-up. Thus, molecular testing represents an essential tool in differential diagnosis of RASophaties. This view is further strengthened by the increasing accessibility of new sequencing techniques.Finally, to our knowledge, the described case represents the third report of the occurrence of Arnold Chiari malformation and the second description of syringomyelia with LEOPARD syndrome.
RAS 相关疾病的诊断仍然具有挑战性。然而,临床医生已经做出了许多努力来识别特定的临床特征,这些特征可能有助于区分一种疾病与另一种疾病。在这里,我们描述了一个最初被诊断为神经纤维瘤病-诺顿综合征的儿童。对先证者的随访、他父亲的临床评估以及逐个基因检测方法,使我们做出了正确的诊断。
我们报告了一例 8 岁男性,其具有多发性咖啡牛奶斑、多个色素痣和提示诺顿综合征的畸形特征,最初被诊断为神经纤维瘤病-诺顿综合征。然而,经过几年的临床和眼科随访,缺乏典型的 1 型神经纤维瘤病特征和 NF1 突变的缺失促使我们重新考虑最初的诊断。对患者及其同样受影响的父亲(最初被认为是健康的)进行了新的检查,使我们怀疑 LEOPARD 综合征。该诊断随后被患者和他同样受影响的父亲均发生的杂合突变 c.1403 C > T,p.(Thr468Met),即 PTPN11 证实。随后,该先证者还被发现存在 1 型 Arnold-Chiari 畸形伴脊髓空洞症。
我们的经验表明,RAS 相关疾病之间的鉴别临床诊断仍然存在模糊性,并对当前的诊断临床标准提出了质疑。在某些情况下,基因测试是正确诊断的唯一确凿证据,因此也是确定个体预后和提供适当随访的唯一证据。因此,分子检测是 RAS 相关疾病鉴别诊断的重要工具。这一观点因新测序技术的日益普及而得到进一步加强。最后,据我们所知,所描述的病例代表了第三例 Arnold Chiari 畸形的发生和第二例 LEOPARD 综合征伴脊髓空洞症的描述。